Perrigo Company (PRGO) shares were up more than 1% in recent trade after saying the U.S. Food and Drug Administration has approved its abbreviated new drug application for the azelastine hydrochloride nasal spray.
PRGO is trading in the lower half of the 52-week range between $125.37 and $168.39.
The Ireland-based maker of generic drugs said it and Impax Laboratories (IPXL) will share costs and benefits related to the products. The nasal spray is for people over 12 years with nasal symptoms caused by seasonal allergies or environmental irritants
Latest posts by Kevin Calderon (see all)
- The Elysium Star II Will Be Offering A Memorial Service In Space - May 21, 2017
- Study Warns About NSAIDs By Linking Them To Heart Attacks - May 12, 2017
- Video Presents Orca Pod That Set Out On A Killing Spree - May 3, 2017